Termine
Performance
26.11.2021

06.12.21 Vonovia SE
Analystenveranstaltung
06.12.21 Vonovia SE
Analystenveranstaltung
06.12.21 HomeToGo SE
UBS Global TMT Virtual Conference
06.12.21 Advanced Energy Industries, Inc.
Standard Event
06.12.21 Global Fashion Group S.A.
Analysts' Conference
06.12.21 home24 SE
Analystenveranstaltung
06.12.21 Ichor Holdings, Inc.
Analysts' Conference
06.12.21 BIKE24 Holding AG
Roadshow
06.12.21 ENCAVIS AG
Roadshow
06.12.21 Instone Real Estate Group SE
Roadshow
06.12.21 SANHA GmbH & Co. KG
Zinszahlungstermin

November

KW M D M D F S S
44 1 2 3 4 5 6 7
45 8 9 10 11 12 13 14
46 15 16 17 18 19 20 21
47 22 23 24 25 26 27 28
48 29 30          

Dezember

KW M D M D F S S
48     1 2 3 4 5
49 6 7 8 9 10 11 12
50 13 14 15 16 17 18 19
51 20 21 22 23 24 25 26
52 27 28 29 30 31    

Januar 2022

KW M D M D F S S
52           1 2
1 3 4 5 6 7 8 9
2 10 11 12 13 14 15 16
3 17 18 19 20 21 22 23
4 24 25 26 27 28 29 30
5 31            

 

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie

3U HOLDING AG

Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021